Article
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.
Molecular psychiatry - 1 May 2013
Revel F G, Moreau J-L, Pouzet B, Mory R, Bradaia A, Buchy D, Metzler V, Chaboz S, Groebke Zbinden K, Galley G, Norcross R D, Tuerck D, Bruns A, Morairty S R, Kilduff T S, Wallace T L, Risterucci C, Wettstein J G, Hoener M C
Abstract excerpt
Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments manage the positive symptoms, yet have minimal effects on the negative and cognitive symptoms, two prominent features of the disease with critical impact on the long-term morbidity. In addition, antipsychotic treatments trigger serious side effects that precipitate treatment discontinuation. Here, we show that activation of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.